1Kumar S, Eoulton AJ, Beck - Nielsen H, et al. Troglitazone, an insulin action enhancer,improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia, 1996, 39:701-709.
2Schwartz S, Raskin P, Fonseca V, et al. Effects of troglitazone in insulin-treated patients with type lidiabetes mellitus: Troglitazone and Exogenous Insulin Study Group. N Engl J Med, 1998, 338:861-866.
3Nicholas SB, Kawano Y, Wakino S, et al.Expression and Function of Pemxisome pm-liferator-activated receptor-γ in mesangial cells. Hypertension, 2001,37: 722-727.
5Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbttminuria in patients with incipient diabetic nephropathy.Diabetes Care, 1998,21:2135-2139.
6Fujii M, Takemura R, Yamaguchi M, et al.Troglitazone( CS-045 ) ameliorates albuminuria in streptozotocin-induced diabetic rats.Metabolism, 1997, 46:981-983.
7Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulinsensitizing action in diabetic rats. Diabetes,2000,49: 1022-1032.
8Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int,2001,59 ; 1899-1910.
9Yoshimoto T, Naruse M, Nishikawa, et al.Antihypertensive and vasculo and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol, 1997,272 : E989-E996.
10Asano T, Wakisaka M, Yoshinari M, et al. Peroxisomeproliferators-activated recept-orγ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiation. Biochimica et. BiophysicaActa,2000,1497:148-154.
